Kigamicin D
Kigamicin D shows activity against Gram-positive bacteria including methicillin-resistant Staphylococcus aureus (MRSA) with MICs of 0.025-0.78 μg/mL. Kigamicin D also shows effect against L-1210 LB32T and other genera tumor cells with IC50 of 1 μg/mL[1].
Product Specifications
CAS Number
[680571-52-2]
UNSPSC
12352005
Target
Bacterial
Related Pathways
Anti-infection
Field of Research
Cancer; Infection
Smiles
OC1=C2C3=C(OCO[C@]3([H])CC4=CC(C[C@@]5(N(CCO5)C6=O)C)=C6C(O)=C42)C7=C1C(C8=C([C@H]([C@@H](C[C@@H]8O)O[C@@H]9O[C@@H]([C@H](CC9)O[C@H]%10C[C@H]([C@@H]([C@H](O%10)C)O[C@H]%11C[C@H]([C@@H]([C@H](O%11)C)O)OC)OC)C)O)O7)=O
Molecular Formula
C48H59NO19
Molecular Weight
953.98
References & Citations
[1]Jie Lu, et al. Kigamicin D, a novel anticancer agent based on a new anti-austerity strategy targeting cancer cells' tolerance to nutrient starvation. Cancer Sci. 2004 Jun;95 (6) :547-52.
Shipping Conditions
Room temperature
Scientific Category
Natural Products
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
GTR15199582 1 Vial
Lentiviral mouse Mlip shRNA (UAS) - Lentiviral mouse Mlip shRNA (UAS, GFP) plasmid
Ask
View Details 325146-01 50 µL
NAB2 (MADER, NGFI-A-binding protein 2, EGR-1-binding protein 2, Melanoma-associated delayed early response protein, Protein MADER)
Ask
View Details